Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD [ updated 2019]. Available from: https://goldcopd.org/gold-reports/. Accessed 710, 2019.
   Google Scholar
• Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis. 2011;6:259–267. doi:10.2147/COPD.S1077121814462
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA. 1994;272(19):1497–1505. doi:10.1001/jama.1994.035201900430337966841
   PubMed Web of Science ®Google Scholar
• Nrdini S, Camiciottoli G, Locicero S, et al. COPD: maximization of bronchodilation. Multidiscip Respir Med. 2014;9(1):50. doi:10.1186/2049-6958-9-5025364503
   PubMedGoogle Scholar
• Babu KS, Morjaria JB. Emerging therapeutic strategies in COPD. Drug Discov Today. 2015;20(3):371–379. doi:10.1016/j.drudis.2014.11.00325462534
   PubMed Web of Science ®Google Scholar
• Ross CL, Hansel TT. New drug therapies for COPD. Clin Chest Med. 2014;35(1):219–239. doi:10.1016/j.ccm.2013.10.00324507848
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12(7):543–559. doi:10.1038/nrd402523977698
   PubMed Web of Science ®Google Scholar
• Aagha K, Palot A, Sofalvi T, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5(2):85–98. doi:10.1177/204062231351822724587893
   PubMedGoogle Scholar
• Prakash A, Babu KS, Morjaria JB. Novel anti-cholinergics in COPD. Drug Discov Today. 2013;18(21–22):1117–1126. doi:10.1016/j.drudis.2013.07.00523872011
   PubMed Web of Science ®Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64(6–7):457–464. doi:10.1016/s0024-3205(98)00588-810069510
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi:10.1124/pr.111.00458022611179
   PubMed Web of Science ®Google Scholar
• Lavorini F. Inhaled drug delivery in the hands of the patient. J Aerosol Med Pulm Drug Deliv. 2014;27(6):414–418. doi:10.1089/jamp.2014.113225238005
   PubMed Web of Science ®Google Scholar
• Aydemir Y. Assessment of the factors affecting the failure to use inhaler devices before and after training. Respir Med. 2015;109(4):451–458. doi:10.1016/j.rmed.2015.02.01125771037
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, et al. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. Arzneimittelforschung. 2007;57(2):92–100. doi:10.1055/s-0031-129658917396619
   PubMed Web of Science ®Google Scholar
• Masumori N. Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature. Patient Prefer Adherence. 2013;7:111–120. doi:10.2147/PPA.S2816023390360
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Scala C, Venturini PL, et al. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother. 2013;14(10):1383–1397. doi:10.1517/14656566.2013.79693023641864
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805.16055882
   PubMed Web of Science ®Google Scholar
• The Japanese Respiratory Society. Guideline of respiratory function tests – spirometry, flow-volume curve, diffusion capacity of the lung. Nihon Kokyuki Gakkai Zasshi. 2004;Suppl:1–56 [ article in Japanese].
   Google Scholar
• Ohno T, Nakade S, Nakayama K, et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol. 2008;65(2):197–202. doi:10.1111/j.1365-2125.2007.02999.x18251758
   PubMed Web of Science ®Google Scholar
• Machida K, Sadamura Y, Mizuno K, Higashimoto I, Inoue H. Bronchodilator efficacy of single administration of oral anticholinergic agent in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:A2919.
   Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. doi:10.1081/COPD-20005337717136971
   PubMedGoogle Scholar
• Zaitsu M, Mikami K, Ishida N, et al. Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST study). Adv Urol. 2011;2011:854697. doi:10.1155/2011/85469722046182
   PubMedGoogle Scholar
• Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008;15(9):809–815. doi:10.1111/j.1442-2042.2008.02104.x18637156
   PubMed Web of Science ®Google Scholar
• Kanayama N, Kanari C, Masuda Y, et al. Drug–drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica. 2007;37(2):139–154. doi:10.1080/0049825060114007217484517
   PubMed Web of Science ®Google Scholar
• Ohno T, Nakade S, Nakayama K, et al. Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients. Drug Metab Pharmacokinet. 2008;23(6):456–463.19122340
   PubMed Web of Science ®Google Scholar
• Volovitz B, Dueñas-Meza E, Chielewska-Szewczyk DA, et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res. 2000;61(7):490–506. doi:10.1016/S0011-393X(00)80032-6
   Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838. doi:10.1136/thx.2007.08604118728206
   PubMed Web of Science ®Google Scholar
• Imamura Y, Kawayama T, Kinoshita T, et al. Poor pharmacological adherence to inhaled medicines compared with oral medicines in Japanese patients with asthma and chronic obstructive pulmonary disease. Allergol Int. 2017;66(3):482–484. doi:10.1016/j.alit.2016.10.00827887878
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495–2517. doi:10.2147/COPD.S9241226604738
   PubMed Web of Science ®Google Scholar
• Karabis A, Lindner L, Mocarski M, et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:405–423. doi:10.2147/COPD.S4896724043936
   PubMed Web of Science ®Google Scholar
• Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012;141(3):745–752. doi:10.1378/chest.11-040621903737
   PubMed Web of Science ®Google Scholar
• Beier J, Mroz R, Kirsten A-M, Chuecos F, Gil EG. Improvement in 24 hr bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. Int J Chron Obstruct Pulmon Dis. 2017;12:1731–1740. doi:10.2147/COPD.S12172328652725
   PubMed Web of Science ®Google Scholar